Takeda Pharmaceutical Company Limited [4502.T]
TOKYO, Jun 01 (Pulse News Wire) – Takeda Pharmaceutical Company Limited (4502.T) withdrew its previous share issuance registration submitted on June 2, 2025, and decided to file a new registration for issuing shares or disposing of treasury shares associated with its Long-Term Incentive Plan (LTIP). The new registration will be valid for up to one year, from June 01, 2026, to June 08, 2027.
The total amount of issuance is capped at ¥240.0 billion. This issuance is intended to support the ongoing implementation of the LTIP as an incentive plan for overseas employees. The funds raised will not be used for financing purposes but rather to fulfill obligations under the LTIP.
Dilution of shares due to rights determinations based on the LTIP and stock award programs introduced since 2014 is estimated to be approximately 1.1% during fiscal year 2026. Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK) focuses on creating innovative medicines across key disease areas such as gastroenterology, inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience, and vaccines. With headquarters in Japan, Takeda operates globally in about 80 countries and regions, adhering to its corporate philosophy centered around patient-centric values shaped over two centuries.
🟢 Confidence: High AI-translated content.